Entroza 1 mg is a potent nonsteroidal aromatase inhibitor used for the treatment of hormone receptor-positive breast cancer in postmenopausal women. By inhibiting aromatase, the enzyme responsible for the conversion of androgens to estrogens, Entroza reduces circulating estrogen levels, thereby depriving estrogen-dependent breast cancer cells of their growth stimulus. It is widely prescribed for early, advanced, or metastatic breast cancer as well as for adjuvant therapy following surgery or other treatments.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Hormonal Chemotherapy

• Aromatase Inhibitor

Indications

Entroza 1 mg is indicated for:

• Postmenopausal women with hormone receptor-positive early or advanced breast cancer

• Metastatic breast cancer in postmenopausal women

• Adjuvant treatment for early breast cancer following surgery

• Patients intolerant or resistant to tamoxifen therapy

It is considered a first-line therapy in postmenopausal women with advanced breast cancer and is also effective for long-term estrogen suppression in adjuvant settings.

Pharmacology

Mechanism of Action:
Entroza 1 mg selectively inhibits the aromatase enzyme, preventing the conversion of androstenedione and testosterone into estrone and estradiol. This results in a significant reduction of circulating estrogen levels, suppressing the growth of estrogen-dependent tumor cells. Unlike ovarian suppression, Entroza does not significantly affect adrenal steroid production.

Pharmacokinetics:

• Absorption: Rapid and nearly complete from the gastrointestinal tract

• Bioavailability: High, unaffected by food

• Protein binding: ~40%

• Metabolism: Primarily hepatic via cytochrome P450 enzymes (CYP3A4)

• Half-life: Approximately 50 hours

• Steady-State Levels: Achieved within 7 days of daily dosing

Dosage & Administration

• Recommended Dose: 1 mg orally once daily, with or without food

• Duration: Continue as long as clinical benefit is observed or until tumor progression

• Special Populations:

  • Hepatic Impairment: No dose adjustment required for mild to moderate impairment; caution advised in severe hepatic dysfunction

  • Renal Impairment: No adjustment necessary for mild to moderate impairment

  • Elderly: Standard dose applicable

    রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

• Minimal clinically significant interactions reported

• Caution when combined with tamoxifen, as it may reduce efficacy

• Potential interaction with drugs metabolized by CYP3A4, requiring monitoring

Contraindications

• Hypersensitivity to anastrozole or any component of the formulation

• Pregnancy and lactation

• Pre-menopausal women, unless combined with ovarian suppression therapy

Side Effects

Most side effects are mild to moderate and are related to estrogen deprivation:

• Common: Hot flashes, arthralgia, fatigue, headache, nausea, edema, and osteoporosis

• Less common: Insomnia, dizziness, mood changes, vaginal dryness, or gastrointestinal upset

• Rare cases of hypercholesterolemia or thromboembolic events have been reported

Precautions & Warnings

• Monitor bone mineral density, as long-term use may increase the risk of osteoporosis

• Caution in patients with pre-existing hepatic or renal impairment

• May cause dizziness or fatigue; patients should exercise caution when driving or operating machinery

• Regular follow-up recommended to monitor for disease progression and side effects

Overdose

• No specific antidote

• Supportive care and monitoring of vital signs recommended

• Gastric lavage or activated charcoal may be considered in cases of significant overdose

Pregnancy & Lactation

• Category D: Use is contraindicated during pregnancy

• Excretion in human milk is unknown; breastfeeding should be avoided while taking Entroza

Storage

• Store below 30°C in a dry place, away from light

• Keep out of reach of children.